260 related articles for article (PubMed ID: 30180893)
1. A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients.
Bisaso KR; Karungi SA; Kiragga A; Mukonzo JK; Castelnuovo B
BMC Med Inform Decis Mak; 2018 Sep; 18(1):77. PubMed ID: 30180893
[TBL] [Abstract][Full Text] [Related]
2. Machine learning to predict virological failure among HIV patients on antiretroviral therapy in the University of Gondar Comprehensive and Specialized Hospital, in Amhara Region, Ethiopia, 2022.
Mamo DN; Yilma TM; Fekadie M; Sebastian Y; Bizuayehu T; Melaku MS; Walle AD
BMC Med Inform Decis Mak; 2023 Apr; 23(1):75. PubMed ID: 37085851
[TBL] [Abstract][Full Text] [Related]
3. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
[TBL] [Abstract][Full Text] [Related]
5. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Doran C; Zhang L
Sex Transm Infect; 2014 Nov; 90(7):538-44. PubMed ID: 24619575
[TBL] [Abstract][Full Text] [Related]
6. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
[TBL] [Abstract][Full Text] [Related]
7. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
[TBL] [Abstract][Full Text] [Related]
8. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
9. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
Ferradini L; Laureillard D; Prak N; Ngeth C; Fernandez M; Pinoges L; Puertas G; Taburet AM; Ly N; Rouzioux C; Balkan S; Quillet C; Delfraissy JF
AIDS; 2007 Nov; 21(17):2293-301. PubMed ID: 18090277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.
Bisson GP; Gross R; Strom JB; Rollins C; Bellamy S; Weinstein R; Friedman H; Dickinson D; Frank I; Strom BL; Gaolathe T; Ndwapi N
AIDS; 2006 Aug; 20(12):1613-9. PubMed ID: 16868442
[TBL] [Abstract][Full Text] [Related]
12. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
13. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
14. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
15. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
Marzolini C; Sabin C; Raffi F; Siccardi M; Mussini C; Launay O; Burger D; Roca B; Fehr J; Bonora S; Mocroft A; Obel N; Dauchy FA; Zangerle R; Gogos C; Gianotti N; Ammassari A; Torti C; Ghosn J; Chêne G; Grarup J; Battegay M;
AIDS; 2015 Jan; 29(2):193-200. PubMed ID: 25426810
[TBL] [Abstract][Full Text] [Related]
16. Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.
Fatti G; Shaikh N; Eley B; Grimwood A
AIDS Care; 2014 Apr; 26(4):448-53. PubMed ID: 24215157
[TBL] [Abstract][Full Text] [Related]
17. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
Gonzalez-Serna A; Glas AC; Brumme CJ; Poon AF; Nohpal De La Rosa A; Mudrikova T; Dias Lima V; Wensing AM; Harrigan R
J Antimicrob Chemother; 2017 Feb; 72(2):496-503. PubMed ID: 27999069
[TBL] [Abstract][Full Text] [Related]
18. Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.
Siefried KJ; Mao L; Kerr S; Cysique LA; Gates TM; McAllister J; Maynard A; de Wit J; Carr A;
PLoS One; 2017; 12(4):e0174613. PubMed ID: 28369066
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
[TBL] [Abstract][Full Text] [Related]
20. Predicting death and lost to follow-up among adults initiating antiretroviral therapy in resource-limited settings: Derivation and external validation of a risk score in Haiti.
McNairy ML; Jannat-Khah D; Pape JW; Marcelin A; Joseph P; Mathon JE; Koenig S; Wells M; Fitzgerald DW; Evans A
PLoS One; 2018; 13(8):e0201945. PubMed ID: 30157197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
